Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

被引：1

作者：

Bodoky, Gyorgy

Gil-Delgado, Marian

Cascinu, Stefano

Lipatov, Oleg N.

Cunningham, David

Van Cutsem, Eric

Muro, Kei

Chandrawansa, Kumari

Liepa, Astra M.

Carlesi, Roberto

Ohtsu, Atsushi

Wilke, Hansjochen

机构：

[1] Szent Laszlo Hosp, Budapest, Hungary

[2] Hop La Pitie Salpetriere, Paris, France

[3] Univ Politecn Marche, Clin Oncol Med, AO Osped Riuniti, Ancona, Italy

[4] Bashkortostan Clin Oncol Ctr, Ufa, Russia

[5] Royal Marsden & Inst Canc Res, London, England

[6] Univ Hosp Leuven, Leuven, Belgium

[7] Katholieke Univ Leuven, Leuven, Belgium

[8] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan

[9] Eli Lilly & Co, Bridgewater, NJ USA

[10] Eli Lilly & Co, Indianapolis, IN 46285 USA

[11] Eli Lilly Italia SpA, Sesto Fiorentino Fl, Italy

[12] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan

[13] Kliniken Essen Mitte Ctr Pallat Care, Essen, Germany

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1